MRTX-1257 (1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg, and 100 mg/kg, orally daily for 30 days) demonstrated rapid tumor growth inhibition in all dose groups in the MIA PaCa-2 mouse G12C xenograft model[1].
MRTX-1257 demonstrated sustained regressions in the 3, 10, 30, and 100 mg/kg dose groups[1].
MRTX-1257 at 100 mg/kg daily resulted in complete responses that were maintained for >70 days after cessation of treatment[1].
| Animal Model: | MIA PaCa-2 G12C Xenograft Model (mouse)[1]. |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg. |
| Administration: | Orally daily for 30 days. |
| Result: | Showed rapid tumor growth inhibition at all dose groups. Showed sustained regression at 3,10, 30, and 100 mg/kg dose groups. 100 mg/kg daily led to complete responses that are maintained >70 days after cessation of treatment. |